Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data.

It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms.

The market opens at 10am (eastern time) and the data is taken at 10:15am, once every ASX stock has commenced trading.



Stocks highlighted in yellow have made market-moving announcements (click headings to sort).

Code Company Price % Volume Market Cap
PNX PNX Metals Limited 0.003 50% 200,000 $10,761,249
SIH Sihayo Gold Limited 0.002 33% 2,495,300 $9,153,192
PTX Prescient Ltd 0.125 29% 1,501,077 $70,399,948
CLZ Classic Min Ltd 0.0025 25% 2,052,862 $2,532,188
TTA TTA Holdings Ltd 0.023 21% 29,891 $2,611,045
EDE Eden Inv Ltd 0.006 20% 875,000 $14,657,222
SLS Solsticeminerals 0.185 19% 90,000 $15,544,455
ADR Adherium Ltd 0.0035 17% 50,281 $14,989,315
WLD Wellard Limited 0.062 15% 24,000 $28,687,517
MYR Myer Holdings Ltd 1.095 15% 3,459,860 $784,321,268
Wordpress Table Plugin

Sihayo Gold (ASX:SIH) has found some solid results in follow-up drilling at its Sihayo Starter Project in North Sumatra, Republic of Indonesia, including 5.0m at 5.50 g/t gold from 257m.

Results from the program will inform an updated Mineral Resource estimate for the deeper higher-grade gold mineralisation, expected to be completed in Q2 CY2023.

The company will also further assess the potential for underground mining opportunities to augment planned open pit mill feed. 

Prescient Therapeutics (ASX:PTX) has been granted Orphan Drug Designation (ODD) from the US Food and Drug Administration for its PTX-100 drug for the treatment of T cell lymphomas. 

ODD is for drugs for the safe and effective treatment, diagnosis or prevention of rare diseases that affect fewer than 200,000 people in the US and is designed to provide benefits to incentivize drug development in less common diseases. 

The benefits include guaranteed market exclusivity of seven years from granting of regulatory approval; and a waiver of Prescription Drug User Fee Act (PDUFA) fees for orphan drugs, which has a value of over US$3.1 million in 2022.

Solstice Minerals (ASX:SLS) has hit an intercept of 1.81m at 23.1% nickel during diamond drilling at the GSP Prospect (GSP) within its Ringlock Dam nickel project in WA.

CEO and MD Nick Castleden says the results validate the prospect as a “live high-tenor nickel sulphide system.” 

“The exploration prize is an intact high-grade footwall massive sulphide body somewhere nearby,” he said.

“We know this ultramafic package can deliver, as evidenced by the historic high-grade Silver Swan deposit located some 30km to the southeast.”



Code Company Price % Volume Market Cap
MCT Metalicity Limited 0.002 -33% 5,000 $10,513,618
ARE Argonaut Resources 0.0015 -25% 729,975 $12,723,743
GTG Genetic Technologies 0.003 -25% 1,250,000 $46,166,633
OAU Ora Gold Limited 0.003 -25% 2,550,000 $3,936,925
AMD Arrow Minerals 0.005 -17% 142,857 $17,449,863
XTC Xantippe Res Ltd 0.005 -17% 3,110,937 $63,480,598
YPB YPB Group Ltd 0.005 -17% 437,366 $2,439,277
BEX Bikeexchange Ltd 0.012 -14% 8,000 $13,045,804
CMG Criticalmineralgrp 0.16 -14% 8,547 $5,649,081
NUH Nuheara Limited 0.18 -12% 322,526 $31,570,637
Wordpress Table Plugin